In this study, investigators from the United States performed a systematic review to assess the efficacy and safety of sibutramine hydrochloride for weight loss.
The team searched MEDLINE, EMBASE, the Cochrane Library, and 7 other computerized bibliographic search tools using the keywords "sibutramine," "Meridia," and "Reductil". They included studies in all languages and for all available years.
The authors and the manufacturer were also contacted.
The team included randomized placebo-controlled trials of sibutramine, 10 to 20 mg per day, in obese adults.
|Diabetic patients had small improvements in glycemic control.|
|Archives of Internal Medicine|
The investigators considered that 29 trials had sufficient data for analysis once unpublished data from 10 authors was included.
The mean weight loss for the 3-month and 1-year trials was 2.78 kg and 4.45 kg, respectively.
One trial found that sibutramine maintained weight loss better than placebo at 2 years.
The investigators found that weight loss with sibutramine was associated with modest increases in heart rate and blood pressure. It was also associated with small improvements in high-density lipoprotein cholesterol and triglycerides levels.
In diabetic patients, small improvements in glycemic control were observed.
There was no direct evidence that sibutramine reduced obesity-associated morbidity or mortality.
Dr David Arterburn's team concluded, "Sibutramine is effective in promoting weight loss".
"Weight loss with sibutramine is associated with both positive and negative changes in cardiovascular and metabolic risk factors".
"There is insufficient evidence to accurately determine the long-term risk-benefit profile for sibutramine".